January 2026 in “British Journal of Clinical Pharmacology”
In this study, reports from individuals using Serenoa repens indicated a possible post-Serenoa syndrome characterized by persistent sexual and neuropsychiatric symptoms, with causality assessed as 'probable' in 54% of cases, highlighting an underrecognized safety concern that warrants further investigation.
This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.
6 citations
,
March 2014 in “Annals of Pharmacotherapy”
This case report suggests that anidulafungin may be associated with hair loss, highlighting the need for physicians to monitor this potential adverse effect.
This case report describes an 11-year-old girl who experienced hot flashes and menarche after taking a Serenoa repens supplement for telogen effluvium, suggesting a possible but uncertain link between the supplement and hormonal changes.